MDGL MADRIGAL PHARMACEUTICALS, INC.
Nasdaq · SEC CIK 1157601 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $81.48M 28 sales by 9 insiders
- Filings on record
- 169 since 2021-08-04, latest 2026-09-11 16:57
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| FRIEDMAN PAUL A | Dir | — | $26.66M |
| Taub Rebecca | Dir | — | $21.68M |
| Sibold William John | Pres, CEO, Dir | — | $10.48M |
| BATE KENNETH | Dir | — | $8.03M |
| Levy Richard S | Dir | — | $7.36M |
| Dier Mardi | EVP, CFO | — | $3.77M |
| Huntsman Carole | Chief Commercial Off | — | $1.71M |
| Soergel David | Chief Medical Off | — | $952.0K |
| Kelley Shannon T | GC | — | $841.6K |
| Thakkar Rita | CAO | — | — |
Transactions 205
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-09-11 16:57 | 2026-09-09+ | MDGL | Sibold William John | Pres, CEO, Dir | S - Sale | $538.65 | -11.6K | 197.7K | -6% | -$6.24M |
| 2026-08-20 16:20 | 2026-08-17 | MDGL | Kelley Shannon T | GC | S - Sale | $514.97 | -664 | 11.5K | -5% | -$341.9K | |
| D | 2026-08-18 17:10 | 2026-08-15 | MDGL | REED JOHN C | Dir | A - Grant | $0.00 | +647 | 647 | New | $0 |
| D | 2026-07-20 21:16 | 2026-07-17 | MDGL | Sibold William John | Pres, CEO, Dir | M - OptEx | — | +50.0K | 211.8K | +31% | — |
| DM | 2026-07-20 21:16 | 2026-07-20 | MDGL | Sibold William John | Pres, CEO, Dir | S - Sale+OE | $547.30 | -2,500 | 209.3K | -1% | -$1.37M |
| D | 2026-06-18 16:23 | 2026-06-17 | MDGL | Taub Rebecca | Dir | A - Grant | $0.00 | +454 | 452.7K | +0.1% | $0 |
| D | 2026-06-18 16:21 | 2026-06-17 | MDGL | Levy Richard S | Dir | A - Grant | $0.00 | +454 | 22.5K | +2% | $0 |
| D | 2026-06-18 16:19 | 2026-06-17 | MDGL | FOUSE JACQUALYN A | Dir | A - Grant | $0.00 | +454 | 1,551 | +41% | $0 |
| D | 2026-06-18 16:16 | 2026-06-17 | MDGL | Daly James M | Dir | A - Grant | $0.00 | +454 | 3,081 | +17% | $0 |
| D | 2026-06-18 16:12 | 2026-06-17 | MDGL | Brennan Daniel J. | Dir | A - Grant | $0.00 | +404 | 1,371 | +42% | $0 |
| DMI | 2026-06-18 16:03 | 2026-06-17 | MDGL | BAKER BROS. ADVISORS LP | Dir | A - Grant | $0.00 | +1,816 | 1.95M | +0.1% | $0 |
| T | 2026-06-01 19:49 | 2026-06-01 | MDGL | Soergel David | Chief Medical Off | S - Sale | $495.74 | -1,042 | 10.0K | -9% | -$516.6K |
| MT | 2026-05-22 18:01 | 2026-05-22 | MDGL | Levy Richard S | Dir | S - Sale | $515.44 | -5,682 | 22.0K | -21% | -$2.93M |
| 2026-05-18 17:36 | 2026-05-18 | MDGL | Soergel David | Chief Medical Off | S - Sale | $515.90 | -844 | 11.1K | -7% | -$435.4K | |
| D | 2026-03-06 | 2026-03-06 | MDGL | Kelley Shannon T | GC | S - Sale | $431.94 | -360 | 12.1K | -3% | -$155.5K |
| D | 2026-03-06 | 2026-03-04 | MDGL | Kelley Shannon T | GC | A - Grant | $0.00 | +4,017 | 12.5K | +47% | $0 |
| D | 2026-03-06 | 2026-03-04 | MDGL | Sibold William John | Pres, CEO, Dir | A - Grant | $0.00 | +15.0K | 163.5K | +10% | $0 |
| D | 2026-03-06 | 2026-03-06 | MDGL | Sibold William John | Pres, CEO, Dir | S - Sale | $431.94 | -1,663 | 161.8K | -1% | -$718.3K |
| DM | 2026-03-06 | 2026-03-06 | MDGL | Dier Mardi | EVP, CFO | S - Sale | $430.87 | -1,982 | 12.8K | -13% | -$854.0K |
| D | 2026-03-06 | 2026-03-04 | MDGL | Dier Mardi | EVP, CFO | A - Grant | $0.00 | +5,215 | 14.5K | +56% | $0 |
| D | 2026-03-06 | 2026-03-04 | MDGL | Soergel David | Chief Medical Off | A - Grant | $0.00 | +4,374 | 11.9K | +58% | $0 |
| 2026-03-06 | 2026-03-06 | MDGL | Taub Rebecca | Dir | S - Sale | $431.94 | -491 | 452.2K | -0.1% | -$212.1K | |
| D | 2026-03-06 | 2026-03-04 | MDGL | Huntsman Carole | Chief Commercial Off | A - Grant | $0.00 | +3,989 | 13.1K | +44% | $0 |
| D | 2026-03-06 | 2026-03-06 | MDGL | Huntsman Carole | Chief Commercial Off | S - Sale | $431.94 | -419 | 12.7K | -3% | -$181.0K |
| 2026-03-02 | 2026-03-02 | MDGL | Dier Mardi | EVP, CFO | S - Sale | $427.21 | -1,183 | 9,257 | -11% | -$505.4K | |
| D | 2026-02-24 | 2026-02-23 | MDGL | Levy Richard S | Dir | M - OptEx | $7.36 | +2,500 | 27.7K | +10% | +$18.4K |
| D | 2026-01-26 | 2026-01-26 | MDGL | Levy Richard S | Dir | M - OptEx | $16.46 | +4,000 | 25.2K | +19% | +$65.8K |
| M | 2026-01-26 | 2026-01-26 | MDGL | Huntsman Carole | Chief Commercial Off | S - Sale | $493.78 | -910 | 9,692 | -9% | -$449.3K |
| 2026-01-26 | 2026-01-26 | MDGL | Taub Rebecca | Dir | S - Sale | $492.42 | -647 | 452.7K | -0.1% | -$318.6K | |
| 2026-01-26 | 2026-01-26 | MDGL | Sibold William John | Pres, CEO, Dir | S - Sale | $492.42 | -1,577 | 148.5K | -1% | -$776.5K | |
| 2026-01-20 | 2026-01-20 | MDGL | Taub Rebecca | Dir | S - Sale | $490.77 | -2,238 | 453.4K | -0.5% | -$1.10M | |
| D | 2026-01-20 | 2026-01-15 | MDGL | Thakkar Rita | CAO | A - Grant | $0.00 | +2,398 | 2,398 | New | $0 |
| M | 2026-01-20 | 2026-01-20 | MDGL | Kelley Shannon T | GC | S - Sale | $497.36 | -692 | 8,910 | -7% | -$344.2K |
| DM | 2026-01-13 | 2026-01-09 | MDGL | Taub Rebecca | Dir | S - Sale+OE | $550.33 | -240 | 455.8K | -0.1% | -$132.1K |
| D | 2026-01-13 | 2026-01-09 | MDGL | Taub Rebecca | Dir | M - OptEx | $15.80 | +240 | 455.8K | +0.1% | +$3,792 |
| DM | 2026-01-13 | 2026-01-09 | MDGL | Taub Rebecca | Dir | S - Sale+OE | $522.40 | -18.4K | 458.9K | -4% | -$9.62M |
| D | 2026-01-13 | 2026-01-09 | MDGL | Taub Rebecca | Dir | M - OptEx | $15.80 | +18.4K | 474.0K | +4% | +$290.9K |
| D | 2026-01-13 | 2026-01-09 | MDGL | FRIEDMAN PAUL A | Dir | M - OptEx | $15.80 | +280 | 187.4K | +0.1% | +$4,424 |
| D | 2026-01-13 | 2026-01-09 | MDGL | FRIEDMAN PAUL A | Dir | S - Sale+OE | $551.24 | -280 | 187.2K | -0.1% | -$154.3K |
| DM | 2026-01-13 | 2026-01-09 | MDGL | FRIEDMAN PAUL A | Dir | S - Sale+OE | $522.39 | -24.5K | 200.3K | -11% | -$12.81M |
| D | 2026-01-13 | 2026-01-09 | MDGL | FRIEDMAN PAUL A | Dir | M - OptEx | $15.80 | +24.5K | 211.7K | +13% | +$387.4K |
| D | 2025-12-12 | 2025-12-10 | MDGL | FRIEDMAN PAUL A | Dir | M - OptEx | $15.80 | +24.8K | 212.0K | +13% | +$391.8K |
| DM | 2025-12-12 | 2025-12-10 | MDGL | FRIEDMAN PAUL A | Dir | S - Sale+OE | $552.18 | -24.8K | 198.9K | -11% | -$13.69M |
| DM | 2025-12-12 | 2025-12-10 | MDGL | Taub Rebecca | Dir | S - Sale+OE | $552.15 | -18.6K | 478.8K | -4% | -$10.30M |
| D | 2025-12-12 | 2025-12-10 | MDGL | Taub Rebecca | Dir | G - Gift | $0.00 | -5,455 | 455.6K | -1% | $0 |
| D | 2025-12-12 | 2025-12-10 | MDGL | Taub Rebecca | Dir | M - OptEx | $15.80 | +18.6K | 479.7K | +4% | +$294.7K |
| D | 2025-12-04 | 2025-12-03 | MDGL | Sibold William John | Pres, CEO, Dir | M - OptEx | — | +50.0K | 152.5K | +49% | — |
| D | 2025-12-04 | 2025-12-04 | MDGL | Sibold William John | Pres, CEO, Dir | S - Sale+OE | $575.34 | -2,400 | 150.1K | -2% | -$1.38M |
| DM | 2025-12-03 | 2025-12-02 | MDGL | Dier Mardi | EVP, CFO | S - Sale+OE | $578.34 | -4,173 | 12.7K | -25% | -$2.41M |
| D | 2025-12-03 | 2025-12-02 | MDGL | Dier Mardi | EVP, CFO | M - OptEx | $251.63 | +4,173 | 14.6K | +40% | +$1.05M |
| M | 2025-11-21 | 2025-11-21 | MDGL | Huntsman Carole | Chief Commercial Off | S - Sale | $553.11 | -1,958 | 10.6K | -16% | -$1.08M |
| DM | 2025-11-14 | 2025-11-13 | MDGL | Levy Richard S | Dir | S - Sale+OE | $520.96 | -8,500 | 21.2K | -29% | -$4.43M |
| DM | 2025-11-14 | 2025-11-13 | MDGL | Levy Richard S | Dir | M - OptEx | $13.78 | +8,500 | 29.7K | +40% | +$117.2K |
| DM | 2025-11-07 | 2025-11-05 | MDGL | BATE KENNETH | Dir | M - OptEx | $205.07 | +16.6K | 19.2K | +631% | +$3.40M |
| DM | 2025-11-07 | 2025-11-05 | MDGL | BATE KENNETH | Dir | S - Sale+OE | $484.31 | -16.6K | 8,896 | -65% | -$8.03M |
| 2025-09-09 | 2025-09-09 | MDGL | Sibold William John | Pres, CEO, Dir | S - Sale | $445.63 | -7,279 | 102.5K | -7% | -$3.24M | |
| M | 2025-08-21 | 2025-08-21 | MDGL | Sibold William John | Pres, CEO, Dir | S - Sale | $400.17 | -7,616 | 109.8K | -6% | -$3.05M |
| MI | 2025-08-20 | 2025-08-18+ | MDGL | Baker Bros. Advisors (GP) LLC | Dir | P - Purchase | $380.58 | +97.1K | 1.95M | +5% | +$36.94M |
| MI | 2025-08-20 | 2025-08-18 | MDGL | BAKER FELIX | Dir | P - Purchase | $364.04 | +68.6K | 1.84M | +4% | +$24.98M |
| M | 2025-08-18 | 2025-08-18 | MDGL | Kelley Shannon T | GC | S - Sale | $367.81 | -1,304 | 9,215 | -12% | -$479.6K |
| DM | 2025-08-15 | 2025-08-15 | MDGL | BATE KENNETH | Dir | S - Sale+OE | $365.20 | -10.0K | 3,523 | -74% | -$3.65M |
| D | 2025-08-15 | 2025-08-15 | MDGL | BATE KENNETH | Dir | M - OptEx | $16.46 | +10.0K | 12.6K | +381% | +$164.6K |
| DM | 2025-08-13 | 2025-08-11+ | MDGL | FRIEDMAN PAUL A | Dir | M - OptEx | $9.45 | +46.8K | 230.8K | +25% | +$442.3K |
| DM | 2025-08-13 | 2025-08-11+ | MDGL | FRIEDMAN PAUL A | Dir | S - Sale+OE | $355.31 | -46.8K | 222.9K | -17% | -$16.63M |
| D | 2025-08-13 | 2025-08-13 | MDGL | FRIEDMAN PAUL A | Dir | M - OptEx | $9.45 | +129.2K | 316.3K | +69% | +$1.22M |
| DM | 2025-08-13 | 2025-08-13 | MDGL | FRIEDMAN PAUL A | Dir | S - Sale+OE | $370.24 | -129.2K | 187.2K | -41% | -$47.83M |
| DM | 2025-08-13 | 2025-08-11+ | MDGL | Taub Rebecca | Dir | M - OptEx | $9.45 | +46.5K | 504.3K | +10% | +$439.1K |
| DM | 2025-08-13 | 2025-08-11+ | MDGL | Taub Rebecca | Dir | S - Sale+OE | $355.31 | -46.5K | 461.7K | -9% | -$16.51M |
| D | 2025-08-05 | 2025-08-01 | MDGL | Brennan Daniel J. | Dir | A - Grant | $0.00 | +967 | 967 | New | $0 |
| D | 2025-07-22 | 2025-07-18 | MDGL | FRIEDMAN PAUL A | Dir | S - Sale+OE | $350.03 | -1,400 | 187.2K | -0.7% | -$490.0K |
| D | 2025-07-22 | 2025-07-18 | MDGL | FRIEDMAN PAUL A | Dir | M - OptEx | $9.45 | +1,400 | 188.6K | +0.7% | +$13.2K |
| D | 2025-07-22 | 2025-07-18 | MDGL | Taub Rebecca | Dir | S - Sale+OE | $350.01 | -1,000 | 461.0K | -0.2% | -$350.0K |
| D | 2025-07-22 | 2025-07-18 | MDGL | Taub Rebecca | Dir | M - OptEx | $9.45 | +1,000 | 462.0K | +0.2% | +$9,450 |
| DM | 2025-07-18 | 2025-07-16+ | MDGL | Taub Rebecca | Dir | S - Sale+OE | $353.19 | -29.1K | 461.0K | -6% | -$10.28M |
| DM | 2025-07-18 | 2025-07-16+ | MDGL | Taub Rebecca | Dir | M - OptEx | $9.45 | +29.1K | 487.5K | +6% | +$275.0K |
| DM | 2025-07-18 | 2025-07-16+ | MDGL | FRIEDMAN PAUL A | Dir | M - OptEx | $9.45 | +28.9K | 189.9K | +18% | +$272.9K |
| DM | 2025-07-18 | 2025-07-16+ | MDGL | FRIEDMAN PAUL A | Dir | S - Sale+OE | $353.19 | -28.9K | 187.2K | -13% | -$10.20M |
| D | 2025-06-24 | 2025-06-20 | MDGL | Levy Richard S | Dir | A - Grant | $0.00 | +715 | 21.2K | +3% | $0 |
| D | 2025-06-24 | 2025-06-20 | MDGL | FOUSE JACQUALYN A | Dir | A - Grant | $0.00 | +203 | 1,097 | +23% | $0 |
| DMI | 2025-06-24 | 2025-06-20 | MDGL | BAKER FELIX | Dir | A - Grant | $0.00 | +2,860 | 188.8K | +2% | $0 |
| D | 2025-06-24 | 2025-06-20 | MDGL | FRIEDMAN PAUL A | Dir | A - Grant | $0.00 | +715 | 187.2K | +0.4% | $0 |
| D | 2025-06-24 | 2025-06-20 | MDGL | BATE KENNETH | Dir | A - Grant | $0.00 | +715 | 2,627 | +37% | $0 |
| D | 2025-06-24 | 2025-06-20 | MDGL | Daly James M | Dir | A - Grant | $0.00 | +715 | 2,627 | +37% | $0 |
| D | 2025-05-16 | 2025-05-15 | MDGL | Soergel David | Chief Medical Off | A - Grant | $0.00 | +7,545 | 7,545 | New | $0 |
| D | 2025-04-11 | 2025-04-10 | MDGL | Levy Richard S | Dir | M - OptEx | $65.06 | +9,470 | 20.5K | +86% | +$616.1K |
| DM | 2025-03-14 | 2025-03-12+ | MDGL | CRAVES FRED B | Dir | S - Sale+OE | $328.54 | -15.5K | 356.2K | -4% | -$5.08M |
| DM | 2025-03-14 | 2025-03-12+ | MDGL | CRAVES FRED B | Dir | M - OptEx | $82.90 | +15.5K | 351.8K | +5% | +$1.28M |
| D | 2025-03-12 | 2025-03-10 | MDGL | FOUSE JACQUALYN A | Dir | A - Grant | $0.00 | +894 | 894 | New | $0 |
| 2025-03-12 | 2025-03-10 | MDGL | Dier Mardi | SVP, CFO | S - Sale | $323.04 | -258 | 10.4K | -2% | -$83.3K | |
| D | 2025-03-07 | 2025-03-05 | MDGL | Sibold William John | Pres, CEO, Dir | A - Grant | $0.00 | +13.1K | 117.4K | +13% | $0 |
| D | 2025-03-07 | 2025-03-05 | MDGL | Kelley Shannon T | GC | A - Grant | $0.00 | +3,187 | 10.5K | +44% | $0 |
| D | 2025-03-07 | 2025-03-05 | MDGL | Huntsman Carole | Chief Commercial Off | A - Grant | $0.00 | +3,386 | 12.0K | +39% | $0 |
| D | 2025-03-07 | 2025-03-05 | MDGL | Taub Rebecca | Pres, CMO, R, D, Dir | A - Grant | $0.00 | +4,382 | 461.0K | +1.0% | $0 |
| D | 2025-03-07 | 2025-03-05 | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | A - Grant | $0.00 | +2,061 | 5,789 | +55% | $0 |
| DM | 2025-03-07 | 2025-03-05 | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale+OE | $341.33 | -14.1K | 10.9K | -56% | -$4.82M |
| DM | 2025-03-07 | 2025-03-05 | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | M - OptEx | $87.49 | +14.1K | 17.8K | +379% | +$1.23M |
| D | 2025-03-07 | 2025-03-05 | MDGL | Dier Mardi | SVP, CFO | A - Grant | $0.00 | +3,784 | 10.7K | +55% | $0 |
| M | 2025-03-05 | 2025-03-03 | MDGL | Huntsman Carole | Chief Commercial Off | S - Sale | $325.98 | -1,834 | 10.4K | -15% | -$597.8K |
| M | 2025-03-05 | 2025-03-03 | MDGL | Dier Mardi | SVP, CFO | S - Sale | $324.96 | -1,961 | 6,914 | -22% | -$637.3K |
| 2025-03-05 | 2025-03-03 | MDGL | Kelley Shannon T | GC | S - Sale | $335.00 | -415 | 7,290 | -5% | -$139.0K |
Purchase Sale Sale after option exercise All abbreviations